← The FootnotesTwo worlds ↗︎

THE BRAIN BEHIND THE RESEARCH

About the author.

I am Yashasvee Chandra, a master’s student in Biopharmaceutical Management at ESCP Business School, with a B.Tech and M.Tech in Biochemical Engineering and Biotechnology from IIT Delhi.

My thesis explores whether the share of board seats held by investor representatives when a biotech company goes public is linked to how soon it is acquired.

Research, within reach

Research should invite people in. This website turns the thesis into short, visual explanations, showing what was found, how the data were built and what the evidence still cannot tell us. Explore the findings or read The Footnotes, at your own pace.

Seeking opportunities in healthcare and life-sciences finance or consulting in Paris and India.

LinkedInView CV

ABOUT THE RESEARCH

Frequently asked questions

Why study companies that listed between 2015 and 2021?

This period provides a sizeable group of biotech listings, with several years to observe what happened afterwards. The frame has 452 companies: 349 in North America and 103 in Europe. The listing window ends in 2021; outcomes are followed through 25 September 2026.

Why use SEC filings?

They are public documents that name directors, major shareholders and the connections between them. The ownership footnotes help establish which investor a director represents. SEC filings cover the US-listed companies; European home-listed companies required other sources.

Why study listed companies rather than private ones?

The question concerns what happens after an IPO. Listing provides a common starting point and detailed disclosures. Private companies, and companies acquired before completing an IPO, fall outside this study.

Read all 24 questions